Toxic shock syndrome in a paediatric intensive care unit over the last 15 years

Laiseca, Laura Butragueño; Morin, M; Valderrama, Estíbaliz Barredo; Romero, Andrés J. Alcaraz

doi:10.1016/j.anpede.2016.10.013

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Online supplemental file presents the risk of bias assessment of the 41 included studies. The majority of studies were rated as high risk of bias overall owing to residual confounding and lack of adjustment for confounding in statistical analyses (37/41, 90%) 2 5 6 10 35–67. Three studies were rated at moderate risk of bias overall7 14 68 and one at low risk of bias overall 11…”

Section: Resultsmentioning

confidence: 99%

Prognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo quantify the prognostic effects of demographic and modifiable factors in streptococcal toxic shock syndrome (STSS).DesignSystematic review and meta-analysis.Data sourcesMEDLINE, EMBASE and CINAHL from inception to 19 September 2022, along with citations of included studies.Eligibility criteriaPairs of reviewers independently screened potentially eligible studies of patients with Group AStreptococcus-induced STSS that quantified the association between at least one prognostic factor and outcome of interest.Data extraction and synthesisWe performed random-effects meta-analysis after duplicate data extraction and risk of bias assessments. We rated the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluation approach.ResultsOne randomised trial and 40 observational studies were eligible (n=1918 patients). We found a statistically significant association between clindamycin treatment and mortality (n=144; OR 0.14, 95% CI 0.06 to 0.37), but the certainty of evidence was low. Within clindamycin-treated STSS patients, we found a statistically significant association between intravenous Ig treatment and mortality (n=188; OR 0.34, 95% CI 0.15 to 0.75), but the certainty of evidence was also low. The odds of mortality may increase in patients ≥65 years when compared with patients 18–64 years (n=396; OR 2.37, 95% CI 1.47 to 3.84), but the certainty of evidence was low. We are uncertain whether non-steroidal anti-inflammatory drugs increase the odds of mortality (n=50; OR 4.14, 95% CI 1.13 to 15.14; very low certainty). Results failed to show a significant association between any other prognostic factor and outcome combination (very low to low certainty evidence) and no studies quantified the association between a prognostic factor and morbidity post-infection in STSS survivors.ConclusionsTreatment with clindamycin and within clindamycin-treated patients, IVIG, was each significantly associated with mortality, but the certainty of evidence was low. Future research should focus on morbidity post-infection in STSS survivors.PROSPERO registration numberCRD42020166961.

show abstract

Section: Resultsmentioning

confidence: 99%